Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2008

Open Access 01-12-2008 | Review

Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy

Authors: R Matthew Chico, Rudiger Pittrof, Brian Greenwood, Daniel Chandramohan

Published in: Malaria Journal | Issue 1/2008

Login to get access

Abstract

In the high malaria-transmission settings of sub-Saharan Africa, malaria in pregnancy is an important cause of maternal, perinatal and neonatal morbidity. Intermittent preventive treatment of malaria in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) reduces the incidence of low birth-weight, pre-term delivery, intrauterine growth-retardation and maternal anaemia. However, the public health benefits of IPTp are declining due to SP resistance. The combination of azithromycin and chloroquine is a potential alternative to SP for IPTp. This review summarizes key in vitro and in vivo evidence of azithromycin and chloroquine activity against Plasmodium falciparum and Plasmodium vivax, as well as the anticipated secondary benefits that may result from their combined use in IPTp, including the cure and prevention of many sexually transmitted diseases. Drug costs and the necessity for external financing are discussed along with a range of issues related to drug resistance and surveillance. Several scientific and programmatic questions of interest to policymakers and programme managers are also presented that would need to be addressed before azithromycin-chloroquine could be adopted for use in IPTp.
Literature
1.
Brabin B: An analysis of malaria in pregnancy in Africa. Bulletin of the World Health Organization. 1983, 61: 1005-1016.PubMedCentralPubMed
2.
McGregor IA: Epidemiology, malaria and pregnancy. Am J Trop Med Hyg. 1984, 33 (4): 517-525.PubMed
3.
Brabin B: The Risks and Severity of Malaria in Pregnant Women. Applied Field Research in Malaria Reports. vol. TDR/FIELDMAL/1. 1991, Geneva: Special Programme for Research and Training in Tropical Diseases. World Health Organization
4.
McGregor IA, Wilson ME, Billewicz WZ: Malaria infection of the placenta in The Gambia, West Africa; its incidence and relationship to stillbirth, birthweight and placental weight. Trans R Soc Trop Med Hyg. 1983, 77 (2): 232-244. 10.1016/0035-9203(83)90081-0.PubMed
5.
Fried M, Muga RO, Misore AO, Duffy PE: Malaria elicits type 1 cytokines in the human placenta: IFN-gamma and TNF-alpha associated with pregnancy outcomes. J Immunol. 1998, 160 (5): 2523-2530.PubMed
6.
Gilles HM, Lawson JB, Sibelas M, Voller A, Allan N: Malaria, anaemia and pregnancy. Ann Trop Med Parasitol. 1969, 63 (2): 245-263.PubMed
7.
Guyatt HL, Snow RW: Malaria in pregnancy as an indirect cause of infant mortality in sub-Saharan Africa. Trans R Soc Trop Med Hyg. 2001, 95 (6): 569-576. 10.1016/S0035-9203(01)90082-3.PubMed
8.
Filler SJ, Kazembe P, Thigpen M, Macheso A, Parise ME, Newman RD, Steketee RW, Hamel M: Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi. J Infect Dis. 2006, 194 (3): 286-293. 10.1086/505080.PubMed
9.
WHO: A Strategic Framework for Malaria Prevention and Control During Pregnancy in the Africa Region. vol. AFR/MAL/04/01. 2004, World Health Organization Regional Office for Africa
10.
Garner P, Gulmezoglu AM: Drugs for preventing malaria in pregnant women. Cochrane Database Syst Rev. 2006, CD000169-4
11.
Darnstadt GL, Bhutta ZA, Cousens S, Adam T, Walker N, de Bernis L: Evidence-based, cost-effective interventions: how many newborn babies can we save?. Lancet. 2005, 365: 977-988. 10.1016/S0140-6736(05)71088-6.
12.
WHO: Assessment and Monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. vol. WHO/HTM/RBM/2003.50. 2003, Geneva: World Health Organization
13.
ter Kuile FO, van Eijk AM, Filler SJ: Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA. 2007, 297 (23): 2603-2616. 10.1001/jama.297.23.2603.PubMed
14.
Tagbor H, Bruce J, Ord R, Randall A, Browne E, Greenwood B, Chandramohan D: Comparison of the therapeutic efficacy of chloroquine and sulphadoxine-pyremethamine in children and pregnant women. Trop Med Int Health. 2007, 12 (11): 1288-1297.PubMed
15.
Vallely A, Vallely L, Changalucha J, Greenwood B, Chandramohan D: Intermittent preventive treatment for malaria in pregnancy in Africa: what's new, what's needed?. Malar J. 2007, 6: 16-10.1186/1475-2875-6-16.PubMedCentralPubMed
16.
Nosten F, McGready R, d'Alessandro U, Bonell A, Verhoeff F, Menendez C, Mutabingwa T, Brabin B: Antimalarial Drugs in Pregnancy: A Review. Current Drug Safety. 2006, 1: 1-15. 10.2174/157488606775252584.PubMed
17.
Ward SA, Sevene EJ, Hastings IM, Nosten F, McGready R: Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis. 2007, 7 (2): 136-144. 10.1016/S1473-3099(07)70025-7.PubMed
18.
Newman RD, Parise ME, Slutsker L, Nahlen B, Steketee RW: Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. Trop Med Int Health. 2003, 8 (6): 488-506. 10.1046/j.1365-3156.2003.01066.x.PubMed
19.
Girard AE, Girard D, English AR, Gootz TD, Cimochowski CR, Faiella JA, Haskell SL, Retsema JA: Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother. 1987, 31 (12): 1948-1954.PubMedCentralPubMed
20.
Dunn CJ, Barradell LB: Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs. 1996, 51 (3): 483-505.PubMed
21.
Ballow CH, Amsden GW: Azithromycin: the first azalide antibiotic. Ann Pharmacother. 1992, 26 (10): 1253-1261.PubMed
22.
Peters DH, Friedel HA, McTavish D: Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1992, 44 (5): 750-799. 10.2165/00003495-199244050-00007.PubMed
23.
Sidhu AB, Sun Q, Nkrumah LJ, Dunne MW, Sacchettini JC, Fidock DA: In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. J Biol Chem. 2007, 282 (4): 2494-2504. 10.1074/jbc.M608615200.PubMed
24.
Ramsey PS, Vaules MB, Vasdev GM, Andrews WW, Ramin KD: Maternal and transplacental pharmacokinetics of azithromycin. Am J Obstet Gynecol. 2003, 188 (3): 714-718. 10.1067/mob.2003.141.PubMed
25.
Heikkinen T, Laine K, Neuvonen PJ, Ekblad U: The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. BJOG. 2000, 107 (6): 770-775. 10.1111/j.1471-0528.2000.tb13339.x.PubMed
26.
Weiner C, Buhimschi C: Drugs for Pregnant and Lactating Women. 2004, New York: Churchill Livingston
27.
Dahl EL, Rosenthal PJ: Apicoplast translation, transcription and genome replication: targets for antimalarial antibiotics. Trends Parasitol. 2008, 24 (6): 279-284. 10.1016/j.pt.2008.03.007.PubMed
28.
Schlünzen F, Harms JM, Franceschi F, Hansen HA, Bartels H, Zarivach R, Yonath A: Structural basis for the antibiotic activity of ketolides and azalides. Structure. 2003, 11: 329-338. 10.1016/S0969-2126(03)00022-4.PubMed
29.
Retsema J, Fu W: Macrolides: structures and microbial targets. International Journal of Antimicrobial Agents. 2001, 18 (Suppl 1): 3-10. 10.1016/S0924-8579(01)00401-0.
30.
Pitsouni E, Iavazzo C, Athanasiou S, Falagas ME: Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2007, 30 (3): 213-221. 10.1016/j.ijantimicag.2007.04.015.PubMed
31.
Oldfield EC, Fessel WJ, Dunne MW, Dickinson G, Wallace MR, Byrne W, Chung R, Wagner KF, Paparello SF, Craig DB, Melcher G, Zajdowicz M, Williams RF, Kelly JW, Zelasky M, Heifets LB, Berman JD: Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin Infect Dis. 1998, 26 (3): 611-619. 10.1086/514566.PubMed
32.
Tseng AL, Dolovich L, Salit IE: Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus. Clin Infect Dis. 1997, 24 (1): 76-77.PubMed
33.
34.
Duff P: Antibiotic selection in obstetric patients. Infect Dis Clin North Am. 1997, 11 (1): 1-12. 10.1016/S0891-5520(05)70338-X.PubMed
35.
Ogasawara KK, Goodwin TM: Efficacy of azithromycin in reducing lower genital Ureaplasma urealyticum colonization in women at risk for preterm delivery. J Matern Fetal Med. 1999, 8 (1): 12-16. 10.1002/(SICI)1520-6661(199901/02)8:1<12::AID-MFM3>3.0.CO;2-8.PubMed
36.
Donders GG: Treatment of sexually transmitted bacterial diseases in pregnant women. Drugs. 2000, 59 (3): 477-485. 10.2165/00003495-200059030-00005.PubMed
37.
Sidhu ABS, Dunne MW, Lewis DE, Fidock DA: Identification of a novel mutation in the L4 plastid ribosomal protein in P. falciparum azithromycin-resistant lines. 54th Annual Meeting of the American Society of Topical Medicine and Hygiene. 2005, Washington DC: Albert Einstein College of Medicine and Pfizer Inc
38.
Gingras B, Jensen J: Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Am J Trop Med Hygiene. 1992, 47: 378-382.
39.
Gingras B, Jensen J: Antimalarial activity of azithromycin and erythromycin against Plasmodium burghei. Am J Trop Med Hyg. 1993, 49 (1): 101-105.PubMed
40.
Taylor WR, Richie TL, Fryauff DJ, Picarima H, Ohrt C, Tang D, Braitman D, Murphy GS, Widjaja H, Tjitra E, Ganjar A, Jones TR, Basri H, Berman J: Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis. 1999, 28: 74-81. 10.1086/515071.PubMed
41.
Heppner DG, Walsh DS, Uthaimongkol N, Tang DB, Tulyayon S, Permpanich B, Wimonwattrawatee T, Chuanak N, Laoboonchai A, Sookto P, Brewer TG, McDaniel P, Eamsila C, Yongvanitchit K, Uhl K, Kyle DE, Keep LW, Miller RE, Wongsrichanalai C: Randomized, controlled, double-blind trial of daily oral azithromycin in adults for the prophylaxis of Plasmodium vivax malaria in Western Thailand. Am J Trop Med Hyg. 2005, 73 (5): 842-849.PubMed
42.
Kuschner R, Heppner D, Andersen S, Wellde B, Hall T, Schneider I, Ballou W, Foulds G, Sadoff J, Schuster B: Azithromycin prophylaxis against a chloroquine resistant strain of Plasmodium falciparum. Lancet. 1994, 343 (8910): 1396-1397. 10.1016/S0140-6736(94)92526-7.PubMed
43.
Anderson S, Berman J, Kuschner R, Wesche D, Magill A, Wellde B, Schneider I, Dunne M, Schuster B: Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Ann Intern Med. 1995, 123: 771-773.PubMed
44.
Andersen SL, Oloo AJ, Gordon DM, Ragama OB, Aleman GM, Berman JD, Tang DB, Dunne MW, Shanks GD: Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis. 1998, 26 (1): 146-150. 10.1086/516281.PubMed
45.
Krishna S, White NJ: Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet. 1996, 30 (4): 263-299. 10.2165/00003088-199630040-00002.PubMed
46.
Dollery D, (ed.): Therapeutic drugs. 1999, Edinburgh, UK: Churchill Livingstone
47.
Krogstad DJ, Schlesinger PH: Acid-vesicle function, intracellular pathogens, and the action of chloroquine against Plasmodium falciparum. N Engl J Med. 1987, 317 (9): 542-549.PubMed
48.
Sidhu AB, Verdier-Pinard D, Fidock DA: Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science. 2002, 298 (5591): 210-213. 10.1126/science.1074045.PubMedCentralPubMed
49.
Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naude B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE: Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000, 6 (4): 861-871. 10.1016/S1097-2765(05)00077-8.PubMedCentralPubMed
50.
Jaeger A: Poisonous substances: Quinine and chloroquine. Medicine. 2007, 35: 652-653. 10.1016/j.mpmed.2007.09.023.
51.
Sowunmi A, Walker O, Salako LA: Pruritus and antimalarial drugs in Africans. Lancet. 1989, 2 (8656): 213-10.1016/S0140-6736(89)90391-7.PubMed
52.
Mutabingwa T, Villegas L, Nosten F: Chemoprophylaxis and other protective measures: Preventing pregnancy malaria. Malaria in Pregnancy: Deadly Parasite, Susceptible Host. Edited by: Duffy P, Fried M. 2001, London: Taylor and Francis, 189-222.
53.
Helitzer-Allen DL, Macheso A, Wirima J, Kendall C: Testing strategies to increase use of chloroquine chemoprophylaxis during pregnancy in Malawi. Acta Trop. 1994, 58 (3–4): 255-266. 10.1016/0001-706X(94)90019-1.PubMed
54.
Kaseje DC, Sempebwa EK, Spencer HC: Malaria chemoprophylaxis to pregnant women provided by community health workers in Saradidi, Kenya. I. Reasons for non-acceptance. Ann Trop Med Parasitol. 1987, 81 (Suppl 1): 77-82.PubMed
55.
Mita T, Kaneko A, Lum JK, Bwijo B, Takechi M, Zungu IL, Tsukahara T, Tanabe K, Kobayakawa T, Bjorkman A: Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Am J Trop Med Hyg. 2003, 68 (4): 413-415.PubMed
56.
Takechi M, Matsuo M, Ziba C, MacHeso A, Butao D, Zungu IL, Chakanika I, Bustos MD: Therapeutic efficacy of sulphadoxine/pyrimethamine and susceptibility in vitro of P. falciparum isolates to sulphadoxine-pyremethamine and other antimalarial drugs in Malawian children. Trop Med Int Health. 2001, 6 (6): 429-434. 10.1046/j.1365-3156.2001.00735.x.PubMed
57.
Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, Coulibaly D: A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001, 344 (4): 257-263. 10.1056/NEJM200101253440403.PubMed
58.
Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV: Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis. 2003, 187 (12): 1870-1875. 10.1086/375419.PubMed
59.
Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV: Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med. 2006, 355 (19): 1959-1966. 10.1056/NEJMoa062032.PubMed
60.
Hastings IM, Donnelly MJ: The impact of antimalarial drug resistance mutations on parasite fitness, and its implications for the evolution of resistance. Drug Resist Updat. 2005, 8 (1–2): 43-50. 10.1016/j.drup.2005.03.003.PubMed
61.
Laufer MK, Plowe CV: Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies. Drug Resist Updat. 2004, 7 (4–5): 279-288. 10.1016/j.drup.2004.08.003.PubMed
62.
Walliker D, Hunt P, Babiker H: Fitness of drug-resistant malaria parasites. Acta Trop. 2005, 94 (3): 251-259.PubMed
63.
Denoeud L, Fievet N, Aubouy A, Ayemonna P, Kiniffo R, Massougbodji A, Cot M: Is chloroquine chemoprophylaxis still effective to prevent low birth weight? Results of a study in Benin. Malar J. 2007, 6: 27-10.1186/1475-2875-6-27.PubMedCentralPubMed
64.
Tagbor H, Bruce J, Browne E, Randal A, Greenwood B, Chandramohan D: Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial. Lancet. 2006, 368 (9544): 1349-1356. 10.1016/S0140-6736(06)69559-7.PubMed
65.
Ohrt C, Willingmyre GD, Lee P, Knirsch C, Milhous W: Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 2002, 46 (8): 2518-2524. 10.1128/AAC.46.8.2518-2524.2002.PubMedCentralPubMed
66.
Cook JA, Randinitis EJ, Bramson CR, Wesche DL: Lack of a pharmacokinetic interaction between azithromycin and chloroquine. Am J Trop Med Hyg. 2006, 74 (3): 407-412.PubMed
67.
Martin SK, Oduola AM, Milhous WK: Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science. 1987, 235 (4791): 899-901. 10.1126/science.3544220.PubMed
68.
Bray PG, Boulter MK, Ritchie GY, Howells RE, Ward SA: Relationship of global chloroquine transport and reversal of resistance in Plasmodium falciparum. Mol Biochem Parasitol. 1994, 63 (1): 87-94. 10.1016/0166-6851(94)90011-6.PubMed
69.
Pachot JI, Botham RP, Haegele KD, Hwang K: Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J Pharm Pharm Sci. 2003, 6 (1): 1-12.PubMed
70.
Dunne MW, Singh N, Shukla M, Valecha N, Bhattacharyya PC, Dev V, Patel K, Mohapatra MK, Lakhani J, Benner R, Lele C, Patki K: A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India. J Infect Dis. 2005, 191 (10): 1582-1588. 10.1086/429343.PubMed
71.
Lewis D, Mulenga M, Oduro A, Mugyenyi P, Wasunna M, Kokwaro G, Aman R, Sagara I, Nambozi M, Ansah P, Kityo C, Dunne M: A Phase 2/3, Randomized, Double Blind, Comparative Trial of Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Africa. 5th European Congress on Tropical Medicine and International Health. Amsterdam. 2007
72.
Chandra R, Lewis D, Oduro A, Mulenga M, Sagara I, Sie A, Tiono A, Dieng Y, Ogutu B, Sarkar S, Djimde A, Ansha P, Nambozi M, Zoungrana A, Ouedraogo A, Fall M, Tina LO, Dunne M: A Phase 3, Randomized, Open-Label, Comparative Trial of Azithromycin plus Chloroquine versus Mefloquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Africa. 56th Annual Meeting of the American Society of Topical Medicine and Hygiene. 2007, Philadelphia: Pfizer Inc
73.
Kolaczinski JH, Ojok N, Opwonya J, Meek S, Collins A: Adherence of community caretakers of children to pre-packaged antimalarial medicines (HOMAPAK) among internally displaced people in Gulu district, Uganda. Malar J. 2006, 5: 40-10.1186/1475-2875-5-40.PubMedCentralPubMed
74.
Orton L, Barnish G: Unit-dose packaged drugs for treating malaria. Cochrane Database Syst Rev. 2005, CD004614-2
75.
Connor J, Rafter N, Rodgers A: Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ. 2004, 82 (12): 935-939.PubMedCentralPubMed
76.
McDonald HP, Garg AX, Haynes RB: Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002, 288 (22): 2868-2879. 10.1001/jama.288.22.2868.PubMed
77.
Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF: Piperaquine: a resurgent antimalarial drug. Drugs. 2005, 65 (1): 75-87. 10.2165/00003495-200565010-00004.PubMed
78.
Nakornchai S, Konthiang P: Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 2006, 100 (3): 185-191. 10.1016/j.actatropica.2006.10.008.PubMed
79.
Rogerson SJ, Mwapasa V, Meshnick SR: Malaria in pregnancy: linking immunity and pathogenesis to prevention. Am J Trop Med Hyg. 2007, 77 (6 Suppl): 14-22.PubMed
80.
Nosten F, Vincenti M, Simpson J, Yei P, Thwai KL, de Vries A, Chongsuphajaisiddhi T, White NJ: The effects of mefloquine treatment in pregnancy. Clin Infect Dis. 1999, 28 (4): 808-815. 10.1086/515183.PubMed
81.
Smoak BL, Writer JV, Keep LW, Cowan J, Chantelois JL: The effects of inadvertent exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army servicewomen. J Infect Dis. 1997, 176 (3): 831-833.PubMed
82.
Novartis: Coartem/Riamet. Product monograph: A novel antimalarial combination: one product, two concepts. 2005, Novartis Pharma AG
83.
84.
Mullick S, Watson-Jones D, Beksinska M, Mabey D: Sexually transmitted infections in pregnancy: prevalence, impact on pregnancy outcomes, and approach to treatment in developing countries. Sex Transm Infect. 2005, 81 (4): 294-302. 10.1136/sti.2002.004077.PubMedCentralPubMed
85.
WHO: Sexually transmitted and other reproductive tract infections: Guide to essential practice. 2005, Geneva: Department of Reproductive Health and Research, World Health Organization
86.
Latif AS, Mason PR, Marowa E, Gwanzura L, Chingono A, Mbengeranwa OL: Risk factors for gonococcal and chlamydial cervical infection in pregnant and non-pregnant women in Zimbabwe. Cent Afr J Med. 1999, 45 (10): 252-258.PubMed
87.
Fonck K, Kidula N, Jaoko W, Estambale B, Claeys P, Ndinya-Achola J, Kirui P, Bwayo J, Temmerman M: Validity of the vaginal discharge algorithm among pregnant and non-pregnant women in Nairobi, Kenya. Sex Transm Infect. 2000, 76 (1): 33-38. 10.1136/sti.76.1.33.PubMedCentralPubMed
88.
Gray RH, Wabwire-Mangen F, Kigozi G, Sewankambo NK, Serwadda D, Moulton LH, Quinn TC, O'Brien KL, Meehan M, Abramowsky C, Robb M, Wawer MJ: Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. Am J Obstet Gynecol. 2001, 185 (5): 1209-1217. 10.1067/mob.2001.118158.PubMed
89.
Msuya SE, Mbizvo E, Stray-Pedersen B, Sundby J, Sam NE, Hussain A: Reproductive tract infections among women attending primary health care facilities in Moshi, Tanzania. East Afr Med J. 2002, 79 (1): 16-21.PubMed
90.
Watson-Jones D, Changalucha J, Gumodoka B, Weiss H, Rusizoka M, Ndeki L, Whitehouse A, Balira R, Todd J, Ngeleja D, Ross D, Buve A, Hayes R, Mabey D: Syphilis in pregnancy in Tanzania. I. Impact of maternal syphilis on outcome of pregnancy. J Infect Dis. 2002, 186 (7): 940-947. 10.1086/342952.PubMed
91.
Rastogi S, Das B, Salhan S, Mittal A: Effect of treatment for Chlamydia trachomatis during pregnancy. Int J Gynaecol Obstet. 2003, 80 (2): 129-137. 10.1016/S0020-7292(02)00371-5.PubMed
92.
Sullivan EA, Abel M, Tabrizi S, Garland SM, Grice A, Poumerol G, Taleo H, Chen S, Kaun K, O'Leary M, Kaldor J: Prevalence of sexually transmitted infections among antenatal women in Vanuatu, 1999–2000. Sex Transm Dis. 2003, 30 (4): 362-366. 10.1097/00007435-200304000-00017.PubMed
93.
Plummer FA, Laga M, Brunham RC, Piot P, Ronald AR, Bhullar V, Mati JY, Ndinya-Achola JO, Cheang M, Nsanze H: Postpartum upper genital tract infections in Nairobi, Kenya: epidemiology, etiology, and risk factors. J Infect Dis. 1987, 156 (1): 92-98.PubMed
94.
Blankhart D, Muller O, Gresenguet G, Weis P: Sexually transmitted infections in young pregnant women in Bangui, Central African Republic. Int J STD AIDS. 1999, 10 (9): 609-614. 10.1258/0956462991914753.PubMed
95.
Farley TA, Cohen DA, Elkins W: Asymptomatic sexually transmitted diseases: the case for screening. Prev Med. 2003, 36 (4): 502-509. 10.1016/S0091-7435(02)00058-0.PubMed
96.
Marai W: Lower genital tract infections among pregnant women: a review. East Afr Med J. 2001, 78 (11): 581-585.PubMed
97.
Schulz KF, Cates W, O'Mara PR: Pregnancy loss, infant death, and suffering: legacy of syphilis and gonorrhoea in Africa. Genitourin Med. 1987, 63 (5): 320-325.PubMedCentralPubMed
98.
99.
Mayaud P, ka-Gina G, Cornelissen J, Todd J, Kaatano G, West B, Uledi E, Rwakatare M, Kopwe L, Manoko D, Laga M, Grosskurth H, Hayes R, Mabey D: Validation of a WHO algorithm with risk assessment for the clinical management of vaginal discharge in Mwanza, Tanzania. Sex Transm Infect. 1998, 74 (Suppl 1): S77-84.PubMed
100.
Alary M, Baganizi E, Guedeme A, Padonou F, Davo N, Adjovi C, van Dyck E, Germain M, Joly J, Mahony JB: Evaluation of clinical algorithms for the diagnosis of gonococcal and chlamydial infections among men with urethral discharge or dysuria and women with vaginal discharge in Benin. Sex Transm Infect. 1998, 74 (Suppl 1): S44-49.PubMed
101.
Vuylsteke B, Laga M, Alary M, Gerniers MM, Lebughe JP, Nzila N, Behets F, Van Dyck E, Piot P: Clinical algorithms for the screening of women for gonococcal and chlamydial infection: evaluation of pregnant women and prostitutes in Zaire. Clin Infect Dis. 1993, 17 (1): 82-88.PubMed
102.
Daly CC, Wangel AM, Hoffman IF, Canner JK, Lule GS, Lema VM, Liomba NG, Dallabetta GA: Validation of the WHO diagnostic algorithm and development of an alternative scoring system for the management of women presenting with vaginal discharge in Malawi. Sex Transm Infect. 1998, 74: S50-58. 10.1136/sti.74.1.50.
103.
Wilkinson D, Abdool Karim SS, Harrison A, Lurie M, Colvin M, Connolly C, Sturm AW: Unrecognized sexually transmitted infections in rural South African women: a hidden epidemic. Bull World Health Organ. 1999, 77 (1): 22-28.PubMedCentralPubMed
104.
Kiddugavu MG, Kiwanuka N, Wawer MJ, Serwadda D, Sewankambo NK, Wabwire-Mangen F, Makumbi F, Li X, Reynolds SJ, Quinn TC, Gray RH: Effectiveness of syphilis treatment using azithromycin and/or benzathine penicillin in Rakai, Uganda. Sex Transm Dis. 2005, 32 (1): 1-6. 10.1097/01.olq.0000148297.48590.d8.PubMed
105.
Riedner G, Rusizoka M, Todd J, Maboko L, Hoelscher M, Mmbando D, Samky E, Lyamuya E, Mabey D, Grosskurth H, Hayes R: Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med. 2005, 353 (12): 1236-1244. 10.1056/NEJMoa044284.PubMed
106.
Ratnam AV, Din SN, Hira SK, Bhat GJ, Wacha DS, Rukmini A, Mulenga RC: Syphilis in pregnant women in Zambia. Br J Vener Dis. 1982, 58 (6): 355-358.PubMedCentralPubMed
107.
Zhou P, Qian Y, Xu J, Gu Z, Liao K: Occurrence of congenital syphilis after maternal treatment with azithromycin during pregnancy. Sex Transm Dis. 2007, 34 (7): 472-474. 10.1097/01.olq.0000246314.35047.91.PubMed
108.
Rottingen JA, Cameron DW, Garnett GP: A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known?. Sex Transm Dis. 2001, 28 (10): 579-597. 10.1097/00007435-200110000-00005.PubMed
109.
Gray RH, Wawer MJ: Reassessing the hypothesis on STI control for HIV prevention. Lancet. 2008, 371 (9630): 2064-2065. 10.1016/S0140-6736(08)60896-X.PubMed
110.
Neely M, Kalyesubula I, Bagenda D, Myers C, Olness K: Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission. Afr Health Sci. 2003, 3 (2): 61-67.PubMedCentralPubMed
111.
Semrau K, Kuhn L, Kasonde P, Sinkala M, Kankasa C, Shutes E, Vwalika C, Ghosh M, Aldrovandi G, Thea DM: Impact of chloroquine on viral load in breast milk. Trop Med Int Health. 2006, 11 (6): 800-803. 10.1111/j.1365-3156.2006.01645.x.PubMedCentralPubMed
112.
113.
Hopwood HG: Pneumonia in pregnancy. Obstet Gynecol. 1965, 25: 875-879.PubMed
114.
Goodrum LA: Pneumonia in pregnancy. Semin Perinatol. 1997, 21 (4): 276-283. 10.1016/S0146-0005(97)80070-5.PubMed
115.
Goodnight WH, Soper DE: Pneumonia in pregnancy. Crit Care Med. 2005, 33 (Suppl 10): S390-397. 10.1097/01.CCM.0000182483.24836.66.PubMed
116.
117.
118.
CDC: Sexually Transmitted Disease Surveillance 2006 Supplement, Gonococcal Isolate Surveillance Project (GISP) Annual Report 2006. 2006, Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention
119.
Lau CY, Qureshi AK: Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis. 2002, 29 (9): 497-502. 10.1097/00007435-200209000-00001.PubMed
120.
Mitchell SJ, Engelman J, Kent CK, Lukehart SA, Godornes C, Klausner JD: Azithromycin-resistant syphilis infection: San Francisco, California, 2000–2004. Clin Infect Dis. 2006, 42 (3): 337-345. 10.1086/498899.PubMed
121.
Stamm LV, Bergen HL: A point mutation associated with bacterial macrolide resistance is present in both 23S rRNA genes of an erythromycin-resistant Treponema pallidum clinical isolate. Antimicrob Agents Chemother. 2000, 44 (3): 806-807. 10.1128/AAC.44.3.806-807.2000.PubMedCentralPubMed
122.
Lukehart SA, Godornes C, Molini BJ, Sonnett P, Hopkins S, Mulcahy F, Engelman J, Mitchell SJ, Rompalo AM, Marra CM, Klausner JD: Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med. 2004, 351 (2): 154-158. 10.1056/NEJMoa040216.PubMed
123.
Katz KA, Klausner JD: Azithromycin resistance in Treponema pallidum. Curr Opin Infect Dis. 2008, 21 (1): 83-91.PubMed
124.
Marra CM, Colina AP, Godornes C, Tantalo LC, Puray M, Centurion-Lara A, Lukehart SA: Antibiotic selection may contribute to increases in macrolide-resistant Treponema pallidum. J Infect Dis. 2006, 194 (12): 1771-1773. 10.1086/509512.PubMed
125.
Behets F, van Damme K, Ravelomanana N: Evaluation of azithromycin resistance in T. pallidum isolates from Madagascar [abstract 0-095]. 17th International Society for Sexually Transmitted Diseases Research and 10th International Union Against Sexually Transmitted Infections World Congress. 2007, Seattle, WA: International Society for Sexually Transmitted Diseases Research
126.
Leach AJ, Shelby-James TM, Mayo M, Gratten M, Laming AC, Currie BJ, Mathews JD: A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis. 1997, 24 (3): 356-362.PubMed
127.
Gaynor BD, Chidambaram JD, Cevallos V, Miao Y, Miller K, Jha HC, Bhatta RC, Chaudhary JS, Osaki Holm S, Whitcher JP, Holbrook KA, Fry AM, Lietman TM: Topical ocular antibiotics induce bacterial resistance at extraocular sites. Br J Ophthalmol. 2005, 89 (9): 1097-1099. 10.1136/bjo.2005.068981.PubMedCentralPubMed
128.
Chern KC, Shrestha SK, Cevallos V, Dhami HL, Tiwari P, Chern L, Whitcher JP, Lietman TM: Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area. Br J Ophthalmol. 1999, 83 (12): 1332-1335. 10.1136/bjo.83.12.1332.PubMedCentralPubMed
129.
Gaynor BD, Holbrook KA, Whitcher JP, Holm SO, Jha HC, Chaudhary JS, Bhatta RC, Lietman T: Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. Br J Ophthalmol. 2003, 87 (2): 147-148. 10.1136/bjo.87.2.147.PubMedCentralPubMed
130.
Batt SL, Charalambous BM, Solomon AW, Knirsch C, Massae PA, Safari S, Sam NE, Everett D, Mabey DC, Gillespie SH: Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 2003, 47 (9): 2765-2769. 10.1128/AAC.47.9.2765-2769.2003.PubMedCentralPubMed
131.
Felmingham D, White AR, Jacobs MR, Appelbaum PC, Poupard J, Miller LA, Gruneberg RN: The Alexander Project: the benefits from a decade of surveillance. J Antimicrob Chemother. 2005, 56 (Suppl 2): ii3-ii21. 10.1093/jac/dki297.PubMed
132.
Leclercq R: Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis. 2002, 34 (4): 482-492. 10.1086/324626.PubMed
133.
Feldman C: Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. J Lab Clin Med. 2004, 143 (5): 269-283. 10.1016/j.lab.2004.02.002.PubMed
134.
Bishai W: The in vivo-in vitro paradox in pneumococcal respiratory tract infections. J Antimicrob Chemother. 2002, 49 (3): 433-436. 10.1093/jac/49.3.433.PubMed
135.
Gladue RP, Bright GM, Isaacson RE, Newborg MF: In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother. 1989, 33 (3): 277-282.PubMedCentralPubMed
136.
McCracken GH: Microbiologic activity of the newer macrolide antibiotics. Pediatr Infect Dis J. 1997, 16 (4): 432-437. 10.1097/00006454-199704000-00026.PubMed
137.
Hyde TB, Gay K, Stephens DS, Vugia DJ, Pass M, Johnson S, Barrett NL, Schaffner W, Cieslak PR, Maupin PS, Zell ER, Jorgensen JH, Facklam RR, Whitney CG: Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA. 2001, 286 (15): 1857-1862. 10.1001/jama.286.15.1857.PubMed
Metadata
Title
Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy
Authors
R Matthew Chico
Rudiger Pittrof
Brian Greenwood
Daniel Chandramohan
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2008
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-7-255

Other articles of this Issue 1/2008

Malaria Journal 1/2008 Go to the issue

Research

Cost of increasing access to artemisinin combination therapy: the Cambodian experience

Research

Alterations on peripheral B cell subsets following an acute uncomplicated clinical malaria infection in children

Case study

Prospects, achievements, challenges and opportunities for scaling-up malaria chemoprevention in pregnancy in Tanzania: the perspective of national level officers

Research

Costs and effects of the Tanzanian national voucher scheme for insecticide-treated nets

Research

Plasmodium vivax trophozoites insensitive to chloroquine

Research

Risk factors for house-entry by malaria vectors in a rural town and satellite villages in The Gambia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits